Cullgen Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 115

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $300M

Cullgen General Information

Description

Cullgen Inc is clinical-stage biopharmaceutical company. The company is engaged in the development of medicines for the treatment of diseases lacking effective therapeutic approaches. The company utilizes its technology platform, uSMIT, featuring novel E3 ligands, to build the next generation of targeted protein degraders and to discover and advance therapeutics for the treatment of cancer and other diseases. The products in the company's pipeline include Degrader TRK, Degrader GSPT1, DAC, and others.

Contact Information

Website
www.cullgen.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 12730 High Bluff Drive
  • Suite 250
  • San Diego, CA 92130
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Corporate Office
  • 12730 High Bluff Drive
  • Suite 250
  • San Diego, CA 92130
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cullgen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 04-May-2026 $300M Completed Clinical Trials - Phase 2
6. Reverse Merger 13-Nov-2024 Cancelled Clinical Trials - Phase 2
5. Secondary Transaction - Private 20-Nov-2023 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 13-Apr-2023 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 25-Feb-2021 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 10-Apr-2019 $16M $31M Completed Startup
1. Seed Round 01-Mar-2018 $15M $15M Completed Startup
To view Cullgen’s complete valuation and funding history, request access »

Cullgen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A
Seed 2 5,000,000 $0.000100 $0.08 $1 $1 1x $1 4.69%
Seed 1 10,000,000 $0.000100 $0.08 $1 $1 1x $1 9.38%
To view Cullgen’s complete cap table history, request access »

Cullgen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cullgen Inc is clinical-stage biopharmaceutical company. The company is engaged in the development of medicines for the
Drug Discovery
San Diego, CA
115 As of 2023

San Francisco, CA
 

New Haven, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cullgen Competitors (33)

One of Cullgen’s 33 competitors is Nurix Therapeutics, a Formerly VC-backed company based in San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nurix Therapeutics Formerly VC-backed San Francisco, CA
Arvinas Formerly VC-backed New Haven, CT
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Kymera Therapeutics Formerly VC-backed Watertown, MA
Exo Therapeutics Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 33 competitors. Get the full list »

Cullgen Patents

Cullgen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026041008-A1 Maleic acid derivatives and uses thereof Pending 20-Aug-2024
WO-2025252190-A1 Targeted degraders of werner syndrome recq helicase Pending 07-Jun-2024
EP-4808941-A1 Compounds and methods of treating cancers Pending 16-Nov-2023
WO-2025103502-A1 Compounds and methods of treating cancers Inactive 16-Nov-2023
US-20260297081-A1 Compounds and methods of treating cancers Pending 07-Mar-2023 C07D417/12
To view Cullgen’s complete patent history, request access »

Cullgen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cullgen Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
3E Bioventures (China) Venture Capital Minority
CVI Investments PE/Buyout Minority
GNI Group Corporation Minority
HSG (Hong Kong) Venture Capital Minority
Heights Capital Growth/Expansion Minority
You’re viewing 5 of 17 investors. Get the full list »

Cullgen FAQs

  • When was Cullgen founded?

    Cullgen was founded in 2018.

  • Where is Cullgen headquartered?

    Cullgen is headquartered in San Diego, CA.

  • What is the size of Cullgen?

    Cullgen has 115 total employees.

  • What industry is Cullgen in?

    Cullgen’s primary industry is Drug Discovery.

  • Is Cullgen a private or public company?

    Cullgen is a Private company.

  • What is the current valuation of Cullgen?

    The current valuation of Cullgen is .

  • What is Cullgen’s current revenue?

    The current revenue for Cullgen is .

  • How much funding has Cullgen raised over time?

    Cullgen has raised $116M.

  • Who are Cullgen’s investors?

    3E Bioventures (China), CVI Investments, GNI Group, HSG (Hong Kong), and Heights Capital are 5 of 17 investors who have invested in Cullgen.

  • Who are Cullgen’s competitors?

    Nurix Therapeutics, Arvinas, Sorrento Therapeutics, Kymera Therapeutics, and Exo Therapeutics are some of the 33 competitors of Cullgen.

  • When was Cullgen acquired?

    Cullgen was acquired on 04-May-2026.

  • Who acquired Cullgen?

    Cullgen was acquired by Gyre Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process